Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Risinger has given his Buy rating due to a combination of factors including the promising results from Eli Lilly’s recent clinical trials. The company’s oral small molecule GLP-1, orforglipron, demonstrated a clean safety profile in its Phase 3 study, with liver enzyme elevations comparable to placebo and significant reductions in liver enzymes. This suggests a favorable safety and efficacy profile for orforglipron in treating type 2 diabetes.
Additionally, the Phase 1 results for eloralintide, an injectable amylin receptor agonist, were highly encouraging, showing substantial weight loss and better tolerability compared to other GLP-1 treatments. These positive outcomes from the trials highlight Eli Lilly’s potential for growth and innovation in the pharmaceutical sector, reinforcing the Buy rating on its stock.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $1,100.00 price target.